XNK Therapeutics gets abstract on ACP-001 selected for presentation at EHA2022 ...Middle East

STOCKHOLM, May 2, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association's hybrid...

Hence then, the article about xnk therapeutics gets abstract on acp 001 selected for presentation at eha2022 was published today ( Monday 02/05/2022 - 03:15 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( XNK Therapeutics gets abstract on ACP-001 selected for presentation at EHA2022 )

Also on site :

• Why does Erdogan want a new constitution?
• Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
• Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion